i-Base home
Search Menu
  • Home
  • HTB
  • 2020
  • March
  • 12

HTB

12 March 2020

Contents

Editorial

  • HTB 12 March 2020 now online
  • HTB survey 2020 – please help with feedback

Special reports

  • Fit for purpose: antiretroviral treatment optimisation March 2020
  • HIV pipeline 2020: new drugs in development – March 2020

Conference reports

  • Conference on Retroviruses and Opportunistic Infections (CROI 2020)
  • CROI 2020: Special session on COVID-19
  • Monthly islatravir for PEP and PrEP: 12 pills a year could cover unmet need for HIV prevention in billions of people globally
  • Long-acting cabotegravir and rilpivirine injections support two-monthly dosing
  • Safety and PK of bNAb elipovimab (GS-9722) support two-weekly dosing
  • First results with long-acting capsid inhibitor GS-6207: oral and subcutaneous formulations for use in naïve and multidrug resistance
  • Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
  • Postpartum weight gain is higher with dolutegravir- compared with efavirenz-based ART among African women
  • London patient is second person to be cured of HIV from allogeneic stem-cell transplant
  • The London Patient tells his story as second person cured of HIV

Treatment access

  • Dolutegravir/lamivudine FDC recommended by NHS England

PDFs

  • 12 March 2020 vol 21 no 3
  • HTB RSS

Early access

  • Latest update on HIV and COVID-19 from BHIVA and EACS (January 2021) 15 January 2021
  • Baseline NNRTI resistance linked to poorer response to first-line dolutegravir in the ADVANCE study       14 January 2021
  • Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early 10 January 2021
  • Novavax phase 3 vaccine study launched in the UK, South Africa, US, Mexico and Puerto Rico 10 January 2021
  • All early access reports

Current issues

  • January 2021
  • December 2020
  • November 2020
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook